Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial

Citation:

Doi Y, Hamano T, Yamaguchi S, et al. Diabetes Obes Metab. 2023 Oct;25(10):2944-2953. Epub 2023 Jun 29. PMID: 37385955.